{
    "eid": "2-s2.0-85076196337",
    "title": "Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome\u2013positive chronic myeloid leukemia",
    "cover-date": "2019-12-05",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Biochemistry",
            "@code": "1303",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cell Biology",
            "@code": "1307",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [],
    "authors": [
        "Nobuko Hijiya",
        "Alexey Maschan",
        "Carmelo Rizzari",
        "Hiroyuki Shimada",
        "Carlo Dufour",
        "Hiroaki Goto",
        "Hyoung Jin Kang",
        "Terri Guinipero",
        "Zeynep Karakas",
        "Francisco Bautista",
        "St\u00e9phane Ducassou",
        "Keon Hee Yoo",
        "Christian Michel Zwaan",
        "Fr\u00e9d\u00e9ric Millot",
        "Paola Aimone",
        "Alex Allepuz",
        "Sara Quenet",
        "Florence Hourcade-Potelleret",
        "Sabine Hertle",
        "Darintr Sosothikul"
    ],
    "citedby-count": 24,
    "ref-count": 38,
    "ref-list": [
        "Chronic myeloid leukemia in children: Clinical findings, management, and unanswered questions",
        "Treatment of pediatric chronic myeloid leukemia in the year 2010: Use of tyrosine kinase inhibitors and stem-cell transplantation",
        "Cancer incidence and survival among children and adolescents",
        "Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: Results from a phase III trial",
        "Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial",
        "Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia",
        "Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance",
        "Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia",
        "Nilotinib in pediatric patients with Philadelphia chromosome\u2013positive (Ph1) chronic myeloid leukemia (CML) or Ph1 acute lymphoblastic leukemia (AML): A pharmacokinetic study",
        "Pediatric chronic myeloid leukemia is a unique disease that requires a different approach",
        "AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL",
        "Tyrosine kinase inhibitor\u2013associated cardiovascular toxicity in chronic myeloid leukemia",
        "Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial",
        "Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results",
        "Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial",
        "Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia",
        "Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment",
        "Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty",
        "Growth deceleration in children treated with imatinib for chronic myeloid leukaemia",
        "Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph1 chronic myeloid leukemia in chronic phase",
        "Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children\u2019s Oncology Group",
        "Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: The Italian experience",
        "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia",
        "Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha",
        "The \u201chit hard and hit early\u201d approach to the treatment of chronic myeloid leukemia: Implications of the updated National Comprehensive Cancer Network clinical practice guidelines for routine practice",
        "Pediatric phase I trial and pharmacokinetic study of dasatinib: A report from the Children\u2019s Oncology Group Phase I Consortium",
        "Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: Results from a phase II trial",
        "Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial",
        "Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: A retrospective cohort analysis",
        "How I treat chronic myeloid leukemia in children and adolescents",
        "Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month followup results of a phase II study"
    ],
    "affiliation": [
        {
            "affiliation-city": "Basel",
            "@id": "60009968",
            "affilname": "Novartis International AG",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009968",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Utrecht",
            "@id": "60273130",
            "affilname": "Princess M\u00e1xima Center for Pediatric Oncology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60273130",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60120717",
            "affilname": "Seoul National University Children's Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60120717",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "New York",
            "@id": "60027565",
            "affilname": "Columbia University Irving Medical Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60027565",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Madrid",
            "@id": "60026312",
            "affilname": "Hospital Infantil Universitario Ni\u00f1o Jes\u00fas",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026312",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Yokohama",
            "@id": "60025326",
            "affilname": "Kanagawa Children's Medical Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025326",
            "affiliation-country": "Japan"
        },
        {
            "affiliation-city": "Tokyo",
            "@id": "60025252",
            "affilname": "Keio University School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60025252",
            "affiliation-country": "Japan"
        },
        {
            "affiliation-city": "Talence",
            "@id": "60021564",
            "affilname": "Centre Hospitalier Universitaire de Bordeaux",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021564",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Poitiers",
            "@id": "60020859",
            "affilname": "Centre Hospitalier Universitaire de Poitiers",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020859",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Suwon",
            "@id": "60016329",
            "affilname": "SKKU School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016329",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Genoa",
            "@id": "60016041",
            "affilname": "Istituto Giannina Gaslini",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016041",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Rotterdam",
            "@id": "60015627",
            "affilname": "Erasmus MC Sophia Children's Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015627",
            "affiliation-country": "Netherlands"
        },
        {
            "affiliation-city": "Istanbul",
            "@id": "60012324",
            "affilname": "\u0130stanbul T\u0131p Fak\u00fcltesi",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012324",
            "affiliation-country": "Turkey"
        },
        {
            "affiliation-city": "Milan",
            "@id": "60012306",
            "affilname": "Universit\u00e0 degli Studi di Milano-Bicocca",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012306",
            "affiliation-country": "Italy"
        },
        {
            "affiliation-city": "Columbus",
            "@id": "60003500",
            "affilname": "The Ohio State University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60003500",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": null,
            "@id": "127105848",
            "affilname": "Clinical Development and Analytics",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/127105848",
            "affiliation-country": null
        },
        {
            "affiliation-city": "Moscow",
            "@id": "126797814",
            "affilname": "D. Rogachev Federal Research Center of Pediatric Hematology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126797814",
            "affiliation-country": "Russian Federation"
        },
        {
            "affiliation-city": "Utrecht",
            "@id": "123614327",
            "affilname": "Innovative Therapies for Children with Cancer Consortium",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/123614327",
            "affiliation-country": "Netherlands"
        }
    ],
    "funding": [
        "Martha Hoque and Karen Kaluza Smith",
        "Novartis Pharmaceuticals Corporation"
    ]
}